基因體先驅生物科技股份有限公司 focuses on the research and development of genome modification and cell and stem cell culture technology platforms related to biopharmaceuticals as its core axis. Combining creativity with professionalism, the company innovatively researches and develops medical products that can illuminate human life. Currently, the company's research and development focuses on cancer immunotherapy. Killer T cells in the immune system possess specific and powerful killing capabilities against cancer cells, making them the most critical immune cells used by the human body to fight cancer. Genetically modified immune T-cell therapy (CAR-T) is a novel therapy that takes killer T cells from a patient, genetically modifies them, cultures them in large quantities, and then infuses them back into the patient's body, enabling them to actively identify and annihilate cancer cells. This new therapy "suits the remedy to the case," breaking the traditional old mindset of passively strengthening the patient's own immune system, and actively tailoring for the patient a vanguard of cancer-fighting killer T cells with greater specificity, killing power, and viability. Consequently, its therapeutic efficacy is astonishing, achieving a cure rate of up to 90% in clinical trials for terminal leukemia. CAR-T immunotherapy was even selected by MIT Technology Review as the top of the global top ten technologies in 2016. Therefore, CAR-T immunotherapy will inevitably become the mainstream of future new anti-cancer drugs. CAR-T immunotherapy has become the hottest target in the current international pharmaceutical industry. However, currently all CAR-T therapies use viruses as tools for genome modification, raising safety concerns and resulting in high manufacturing costs. In response to the challenges faced by CAR-T, our company is currently dedicated to researching and developing new-generation CAR-T immunotherapy drugs, hoping to once again subvert the traditional thinking of using viruses as gene therapy vectors through a safer and low-cost non-viral genome modification platform. Currently, the company is actively recruiting promising young talents who possess great enthusiasm for this R&D project to jointly participate in the development of non-viral, next-generation CAR-T immunotherapy, creating the greatest well-being for all mankind.
(The content above was translated by AI.)